Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cusatuzumab plus azacitidine versus azacitidine in higher-risk MDS or CMML
2019-003576-40Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) comparing Cusatuzumab + azacitidine with Azacitidine alone (2 arms). Primary endpoint: Overall response rate. Started Dec 2019; status: terminated.
02
Drugs
cusatuzumabazacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2019-003576-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003576-40.